Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 287

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients

Open access
Böger, Christine, Behrens, Hans-Michael, Mathiak, Micaela, Krüger, Sandra, Kalthoff, Holger, Röcken, Christoph·2016·Oncotarget

Abstract

// Christine Böger 1 , Hans-Michael Behrens 1 , Micaela Mathiak 1 , Sandra Krüger 1 , Holger Kalthoff 2 , Christoph Röcken 1 1 Department of Pathology, Christian-Albrechts-University, Kiel, Germany 2 Department of Experimental Cancer Research, Christian-Albrechts-University, Kiel, Germany Correspondence to: Christoph Röcken, e-mail: christoph.roecken@uksh.de Keywords: programmed death-1, predictive biomarker, immune therapy, pembrolizumab Received: February 03, 2016 Accepted: March 02, 2016 Published: March 18, 2016 ABSTRACT Targeting the PD-1/PD-L1 immune checkpoint signaling is a novel promising treatment strategy in several tumor entities, and it is suggested that PD-L1/PD-1 expression is predictive for a PD-1/PD-L1 checkpoint inhibitor treatment response. We investigated the expression of PD-L1 and PD-1 by immunohistochemistry in a large and well characterized gastric cancer (GC) cohort of Caucasian patients, consisting of 465 GC samples and 15 corresponding liver metastases. Staining results were correlated with clinico-pathological characteristics and survival. PD-L1 expression was found in tumor cells of 140 GCs (30.1%) and 9 liver metastases (60%) respectively in immune cells of 411 GCs (88.4%) and 11 liver metastases (73.3%). PD-1 was expressed in tumor infiltrating lymphocytes in 250 GCs (53.8%) and in 11 liver metastases (73.3%). PD-L1 expression was significantly more prevalent in men, GCs of the proximal stomach, unclassified, papillary, Her2/neu-positive, Epstein-Barr-virus-positive, microsatellite instable, and PIK3CA -mutated GCs. A high PD-L1/PD-1 expression was associated with a significantly better patient outcome, and PD-L1 turned out to be an independent survival prognosticator. The correlation of PD-L1/PD-1 expression with distinct clinico-pathological patient characteristics may serve as a surrogate marker of PD-L1-positive GCs and may direct the use of immune checkpoint treatment strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.8169

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 287

Metadata

Authors
Böger, C., Behrens, H.-M., Mathiak, M., Krüger, S., Kalthoff, H., & Röcken, C.
Venue
Oncotarget
Published
2016-03-18
Volume
7
Issue
17
Pages
24269-24283
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2300582328
Cited by
287
References
28
FWCI
19.16
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. https://app.cochat.ai/papers/10.18632/oncotarget.8169
The paper
Böger, C., Behrens, H.-M., Mathiak, M., Krüger, S., Kalthoff, H., & Röcken, C. (2016). PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. https://doi.org/10.18632/oncotarget.8169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.